HIV Vaccines Market by Vaccine Type (Preventive, Therapeutic), Route Of Administration (Intramuscular, Intranasal, Subcutaneous), Target Antigen, End User - Global Forecast 2025-2032
Description
The HIV Vaccines Market was valued at USD 438.43 million in 2024 and is projected to grow to USD 494.28 million in 2025, with a CAGR of 13.26%, reaching USD 1,187.96 million by 2032.
An authoritative overview of the evolving HIV vaccine ecosystem highlighting integrated technological advances, clinical strategy shifts, and access priorities
The global effort to develop safe, effective, and accessible HIV vaccines has entered a distinct and consequential phase, driven by scientific breakthroughs, cross-sector collaborations, and renewed policy attention. Longstanding challenges-antigenic diversity of HIV, immune escape mechanisms, and the need for durable protective responses-have prompted a shift from single-platform approaches toward integrated strategies that combine antigen design, novel delivery systems, and immune-shaping adjuvants. This era is characterized by an expanded technology palette that includes next-generation mRNA constructs, optimized viral vectors, peptide-based immunogens, and refined protein subunit formulations, each bringing trade-offs in manufacturability, immunogenicity profiles, and deployment logistics.
Simultaneously, clinical trial design is evolving to emphasize adaptive frameworks, correlates of protection, and population-specific endpoints that reflect prevention, treatment, and cure-adjacent objectives. Public health stakeholders, funders, and industry partners are aligning on priorities that balance accelerated development with rigorous safety assessment and equitable access commitments. The cumulative effect is a reordering of competitive advantage: organizations that can integrate advanced immunogen design with scalable manufacturing and nimble regulatory strategy stand to lead the next wave of candidates into pivotal trials and eventual implementation pathways. This introduction sets the stage for deeper analysis of technological inflection points, policy drivers, and operational considerations that will shape strategic decision-making across the HIV vaccine ecosystem.
Critical transformative trends reshaping HIV vaccine development driven by platform innovations, regulatory adaptation, and collaborative financing models
The landscape for HIV vaccines is undergoing transformative shifts that are remapping research, development, and commercialization pathways. Breakthroughs in nucleic acid platforms, particularly conventional and self-amplifying mRNA constructs, have accelerated antigen testing cycles and enabled more complex immunogen designs to address HIV’s genetic variability. At the same time, viral vector platforms and recombinant protein approaches have been refined to improve presentation of conserved epitopes and to harness heterologous prime-boost regimens. These scientific advances are coupled with manufacturing innovations, including modular, high-throughput production systems and improved cold-chain technologies, which collectively reduce technical barriers to scaling candidate vaccines.
Policy and financing paradigms are also shifting, as governments and philanthropic entities emphasize partnerships that de-risk late-stage clinical development while embedding equity and access clauses into funding agreements. Regulatory authorities are increasingly receptive to adaptive trial structures and the use of immune correlates as interim readouts, accelerating go/no-go decisions without compromising safety. Finally, the ecosystem is becoming more collaborative; alliances between biotechs, large pharmaceutical companies, academic consortia, and public health institutions are enabling distributed capabilities-from antigen discovery to local manufacturing-thereby broadening the set of viable development strategies and potential deployment models.
How 2025 tariff changes are reshaping supply chain resilience, manufacturing localization, and distribution strategies across the HIV vaccine ecosystem
The introduction of new tariff measures in 2025 has introduced another layer of complexity for the HIV vaccine value chain, affecting inputs, manufacturing economics, and distribution logistics without altering the fundamental scientific trajectories. Tariff adjustments on imported raw materials, single-use components, and certain biological reagents have increased the administrative and operational burden for manufacturers that rely on globalized supply networks. In particular, manufacturers with concentrated sourcing footprints have experienced longer procurement lead times and higher import clearance costs, prompting strategic reassessments of inventory policies and supplier diversification.
These tariff-driven frictions have incentivized nearshoring and regional manufacturing investments as organizations seek to localize critical steps such as fill-finish, bottling, and cold-chain-enabled packaging. Where local production capabilities exist or can be rapidly developed, stakeholders are prioritizing technology transfer and regulatory alignment to maintain development timelines. Procurement teams are renegotiating contracts to include tariff pass-through clauses and to explore bonded warehousing to mitigate cash flow impacts. On the distribution side, higher cross-border costs have reinforced the attractiveness of direct sales and regional distribution hubs, influencing channel strategies and the allocation of working capital. Taken together, the tariff environment of 2025 has not changed the scientific imperative for effective HIV vaccines, but it has accelerated structural shifts in supply chain design, manufacturing footprint decisions, and commercial route planning.
Precise segmentation insights that align vaccine modality, platform technology, administration route, end-user dynamics, and distribution pathways for strategic prioritization
Segmentation-based insights provide a framework for aligning development priorities with clinical goals, manufacturing realities, and end-user requirements. When viewed through the lens of vaccine type, the market is differentiated between preventive and therapeutic approaches; preventive strategies are further subdivided across inactivated virus, live attenuated virus, recombinant protein, and virus-like particle modalities, each presenting distinct immunogenicity profiles and manufacturing implications. The preventive track places premium emphasis on breadth of protection and durability, while therapeutic programs prioritize immunomodulation and complementary integration with antiretroviral therapy. From a technology perspective, the landscape spans DNA, mRNA, peptide, and viral vector platforms; within mRNA there is a practical distinction between conventional mRNA designs and self-amplifying mRNA constructs, the latter promising dose-sparing potential at the cost of additional formulation considerations.
Routes of administration influence both clinical strategy and deployment logistics, with intramuscular delivery remaining the dominant pathway for systemic immune induction, while intranasal approaches are being evaluated for mucosal immunity and ease of administration, and subcutaneous options offer alternative pharmacokinetic and tolerability profiles. End users include clinics, hospitals, pharmaceutical companies, and research institutes; clinics themselves can be hospital-affiliated or standalone facilities, and hospitals can be classified as private or public providers, a differentiation that affects procurement practices, reimbursement frameworks, and outreach capabilities. Finally, distribution channels span direct sales, online sales, and retail pharmacies, each channel requiring tailored packaging, cold-chain solutions, and regulatory compliance. Synthesizing segmentation insights enables companies to map the trade-offs between immunological objectives and operational constraints, guiding decisions on platform selection, clinical trial site selection, and commercialization pathways.
In-depth regional perspectives on how regulatory environments, manufacturing investments, and clinical site diversity shape HIV vaccine development and deployment
Regional dynamics exert a powerful influence over regulatory timelines, manufacturing capacity planning, and adoption strategies for HIV vaccines. In the Americas, research hubs and biotechnology clusters are accelerating platform innovation while established regulatory frameworks facilitate complex clinical programs; private and academic partnerships in this region are shaping large-scale trial networks and creating commercial channels capable of rapid uptake in urban health systems. Europe, Middle East & Africa present a heterogeneous environment where advanced regulatory agencies coexist with regions facing infrastructure constraints; this complexity has driven multi-jurisdictional regulatory strategies, regional manufacturing hubs, and targeted engagement with public health agencies to ensure clinical trial diversity and culturally appropriate deployment.
Asia-Pacific is characterized by a growing mix of domestic manufacturing capability and large, diverse patient populations suitable for expansive clinical evaluation. Several countries in this region are investing in biomanufacturing capacity and streamlined regulatory support for vaccine candidates, enabling quicker scale-up when candidates transition to late-stage development. Taken together, these regional trends require nuanced approaches to technology transfer, clinical site selection, and community engagement, with an emphasis on aligning trial design to local epidemiology and ensuring logistics planning accounts for region-specific cold-chain and distribution realities.
Strategic company-level insights emphasizing platform leaders, manufacturing partners, funding consortia, and collaborative models that accelerate clinical translation
Leading organizations in the HIV vaccine space are differentiating through integrated capabilities in antigen design, platform optimization, and end-to-end supply chain management. Biotech companies with advanced nucleic acid platforms are pushing iterative design cycles and rapid prototype testing, while established pharmaceutical firms are leveraging manufacturing scale, regulatory expertise, and global commercial networks to prepare for potential large-scale deployment. Strategic partnerships between smaller innovators and large manufacturers are common, combining nimble science with capacity for clinical-grade production and multi-market distribution.
Philanthropic funders, global health agencies, and consortia are playing a critical role in aligning incentives, supporting late-stage trials, and facilitating access-oriented clauses in licensing agreements. Contract development and manufacturing organizations have become essential ecosystem players by offering specialized fill-finish services and flexible capacity that can be repurposed across platforms. Research institutions and clinical consortia contribute essential translational science, enabling the identification of immune correlates and the design of rigorous endpoints for both preventive and therapeutic candidates. Observing these dynamics, organizations that maintain clear collaboration frameworks, prioritize scalable manufacturing partnerships, and invest in regulatory readiness are best positioned to navigate the pathway from candidate selection to real-world implementation.
Actionable recommendations for leaders to fortify R&D agility, scale manufacturing, secure diversified supply chains, and embed equitable access commitments
Industry leaders should adopt a dual-focus strategy that simultaneously accelerates scientific validation and strengthens operational resilience. Prioritize platform diversification to avoid single-point supply vulnerabilities and to enable adaptive prime-boost regimens that harness complementary immunogenic mechanisms. Invest in modular manufacturing architectures and technology transfer capabilities that facilitate rapid scaling and regional production, recognizing that supply chain localization reduces exposure to tariff and logistic disruptions. Establish robust regulatory engagement early in development, leveraging adaptive trial designs and pre-agreed immunological endpoints to shorten decision cycles while maintaining safety standards.
Forge multi-party collaborations that align incentives across biotechs, large manufacturers, funders, and local health systems, ensuring access commitments and capacity building are embedded in development agreements. Optimize distribution pathways by testing channel strategies-direct sales, online ordering for specific markets, and partnerships with retail pharmacies-tailored to regional procurement behaviors and cold-chain realities. Finally, integrate market intelligence and scenario planning into R&D prioritization so that investments in platform research, adjuvant technologies, and administration routes are informed by likely deployment constraints and end-user preferences, thereby increasing the probability of successful adoption when candidates meet clinical endpoints.
Rigorous mixed-methods research methodology combining expert interviews, supply chain mapping, and literature synthesis to support practical decision-making
This report synthesizes primary and secondary research using a mixed-methods approach to ensure analytical rigor and practical relevance. Primary inputs include expert interviews with industry leaders across biotechnology, pharmaceutical manufacturing, clinical research, and public health; structured dialogues with regulatory advisors; and consultations with procurement and supply chain specialists to capture operational realities. Secondary research encompassed peer-reviewed literature on immunology and vaccine platform advances, regulatory guidance documents, and published clinical trial protocols to ground analysis in contemporary scientific and policy frameworks.
Qualitative insights were triangulated with supply chain mapping exercises and technology readiness assessments to identify bottlenecks and opportunities for scale-up. Methodological safeguards included cross-validation of interview findings, a documented audit trail for data sources, and sensitivity checks around assumptions related to manufacturing lead times and distribution scenarios. The result is a synthesis that balances deep technical understanding with pragmatic operational guidance, designed to support decision-makers in R&D planning, partner selection, and commercialization strategy without relying on proprietary market estimates.
A concise synthesis of scientific progress, operational imperatives, and collaborative pathways that together define the current trajectory for HIV vaccines
The ongoing evolution of HIV vaccine development is defined by converging scientific breakthroughs, shifting operational imperatives, and an increasingly collaborative ecosystem. Platform innovations such as conventional and self-amplifying mRNA, refined viral vectors, and advanced protein-based candidates are expanding the toolkit available to researchers and developers, while regulatory and financing shifts are enabling more adaptive and inclusive clinical programs. At the same time, external forces including tariff adjustments and global supply chain realignments are reshaping manufacturing and distribution strategies, emphasizing the importance of supply chain diversification and regional capacity building.
For stakeholders across the spectrum-from early-stage innovators to large manufacturers and health system purchasers-the imperative is to align scientific ambition with operational feasibility. By integrating segmentation-focused strategy, regional contextualization, and pragmatic manufacturing planning, organizations can increase the likelihood that promising candidates will translate into accessible, effective interventions. The collective progress to date suggests that coordinated action across science, policy, and industry practice remains the most credible pathway to achieving meaningful public health impact.
Please Note: PDF & Excel + Online Access - 1 Year
An authoritative overview of the evolving HIV vaccine ecosystem highlighting integrated technological advances, clinical strategy shifts, and access priorities
The global effort to develop safe, effective, and accessible HIV vaccines has entered a distinct and consequential phase, driven by scientific breakthroughs, cross-sector collaborations, and renewed policy attention. Longstanding challenges-antigenic diversity of HIV, immune escape mechanisms, and the need for durable protective responses-have prompted a shift from single-platform approaches toward integrated strategies that combine antigen design, novel delivery systems, and immune-shaping adjuvants. This era is characterized by an expanded technology palette that includes next-generation mRNA constructs, optimized viral vectors, peptide-based immunogens, and refined protein subunit formulations, each bringing trade-offs in manufacturability, immunogenicity profiles, and deployment logistics.
Simultaneously, clinical trial design is evolving to emphasize adaptive frameworks, correlates of protection, and population-specific endpoints that reflect prevention, treatment, and cure-adjacent objectives. Public health stakeholders, funders, and industry partners are aligning on priorities that balance accelerated development with rigorous safety assessment and equitable access commitments. The cumulative effect is a reordering of competitive advantage: organizations that can integrate advanced immunogen design with scalable manufacturing and nimble regulatory strategy stand to lead the next wave of candidates into pivotal trials and eventual implementation pathways. This introduction sets the stage for deeper analysis of technological inflection points, policy drivers, and operational considerations that will shape strategic decision-making across the HIV vaccine ecosystem.
Critical transformative trends reshaping HIV vaccine development driven by platform innovations, regulatory adaptation, and collaborative financing models
The landscape for HIV vaccines is undergoing transformative shifts that are remapping research, development, and commercialization pathways. Breakthroughs in nucleic acid platforms, particularly conventional and self-amplifying mRNA constructs, have accelerated antigen testing cycles and enabled more complex immunogen designs to address HIV’s genetic variability. At the same time, viral vector platforms and recombinant protein approaches have been refined to improve presentation of conserved epitopes and to harness heterologous prime-boost regimens. These scientific advances are coupled with manufacturing innovations, including modular, high-throughput production systems and improved cold-chain technologies, which collectively reduce technical barriers to scaling candidate vaccines.
Policy and financing paradigms are also shifting, as governments and philanthropic entities emphasize partnerships that de-risk late-stage clinical development while embedding equity and access clauses into funding agreements. Regulatory authorities are increasingly receptive to adaptive trial structures and the use of immune correlates as interim readouts, accelerating go/no-go decisions without compromising safety. Finally, the ecosystem is becoming more collaborative; alliances between biotechs, large pharmaceutical companies, academic consortia, and public health institutions are enabling distributed capabilities-from antigen discovery to local manufacturing-thereby broadening the set of viable development strategies and potential deployment models.
How 2025 tariff changes are reshaping supply chain resilience, manufacturing localization, and distribution strategies across the HIV vaccine ecosystem
The introduction of new tariff measures in 2025 has introduced another layer of complexity for the HIV vaccine value chain, affecting inputs, manufacturing economics, and distribution logistics without altering the fundamental scientific trajectories. Tariff adjustments on imported raw materials, single-use components, and certain biological reagents have increased the administrative and operational burden for manufacturers that rely on globalized supply networks. In particular, manufacturers with concentrated sourcing footprints have experienced longer procurement lead times and higher import clearance costs, prompting strategic reassessments of inventory policies and supplier diversification.
These tariff-driven frictions have incentivized nearshoring and regional manufacturing investments as organizations seek to localize critical steps such as fill-finish, bottling, and cold-chain-enabled packaging. Where local production capabilities exist or can be rapidly developed, stakeholders are prioritizing technology transfer and regulatory alignment to maintain development timelines. Procurement teams are renegotiating contracts to include tariff pass-through clauses and to explore bonded warehousing to mitigate cash flow impacts. On the distribution side, higher cross-border costs have reinforced the attractiveness of direct sales and regional distribution hubs, influencing channel strategies and the allocation of working capital. Taken together, the tariff environment of 2025 has not changed the scientific imperative for effective HIV vaccines, but it has accelerated structural shifts in supply chain design, manufacturing footprint decisions, and commercial route planning.
Precise segmentation insights that align vaccine modality, platform technology, administration route, end-user dynamics, and distribution pathways for strategic prioritization
Segmentation-based insights provide a framework for aligning development priorities with clinical goals, manufacturing realities, and end-user requirements. When viewed through the lens of vaccine type, the market is differentiated between preventive and therapeutic approaches; preventive strategies are further subdivided across inactivated virus, live attenuated virus, recombinant protein, and virus-like particle modalities, each presenting distinct immunogenicity profiles and manufacturing implications. The preventive track places premium emphasis on breadth of protection and durability, while therapeutic programs prioritize immunomodulation and complementary integration with antiretroviral therapy. From a technology perspective, the landscape spans DNA, mRNA, peptide, and viral vector platforms; within mRNA there is a practical distinction between conventional mRNA designs and self-amplifying mRNA constructs, the latter promising dose-sparing potential at the cost of additional formulation considerations.
Routes of administration influence both clinical strategy and deployment logistics, with intramuscular delivery remaining the dominant pathway for systemic immune induction, while intranasal approaches are being evaluated for mucosal immunity and ease of administration, and subcutaneous options offer alternative pharmacokinetic and tolerability profiles. End users include clinics, hospitals, pharmaceutical companies, and research institutes; clinics themselves can be hospital-affiliated or standalone facilities, and hospitals can be classified as private or public providers, a differentiation that affects procurement practices, reimbursement frameworks, and outreach capabilities. Finally, distribution channels span direct sales, online sales, and retail pharmacies, each channel requiring tailored packaging, cold-chain solutions, and regulatory compliance. Synthesizing segmentation insights enables companies to map the trade-offs between immunological objectives and operational constraints, guiding decisions on platform selection, clinical trial site selection, and commercialization pathways.
In-depth regional perspectives on how regulatory environments, manufacturing investments, and clinical site diversity shape HIV vaccine development and deployment
Regional dynamics exert a powerful influence over regulatory timelines, manufacturing capacity planning, and adoption strategies for HIV vaccines. In the Americas, research hubs and biotechnology clusters are accelerating platform innovation while established regulatory frameworks facilitate complex clinical programs; private and academic partnerships in this region are shaping large-scale trial networks and creating commercial channels capable of rapid uptake in urban health systems. Europe, Middle East & Africa present a heterogeneous environment where advanced regulatory agencies coexist with regions facing infrastructure constraints; this complexity has driven multi-jurisdictional regulatory strategies, regional manufacturing hubs, and targeted engagement with public health agencies to ensure clinical trial diversity and culturally appropriate deployment.
Asia-Pacific is characterized by a growing mix of domestic manufacturing capability and large, diverse patient populations suitable for expansive clinical evaluation. Several countries in this region are investing in biomanufacturing capacity and streamlined regulatory support for vaccine candidates, enabling quicker scale-up when candidates transition to late-stage development. Taken together, these regional trends require nuanced approaches to technology transfer, clinical site selection, and community engagement, with an emphasis on aligning trial design to local epidemiology and ensuring logistics planning accounts for region-specific cold-chain and distribution realities.
Strategic company-level insights emphasizing platform leaders, manufacturing partners, funding consortia, and collaborative models that accelerate clinical translation
Leading organizations in the HIV vaccine space are differentiating through integrated capabilities in antigen design, platform optimization, and end-to-end supply chain management. Biotech companies with advanced nucleic acid platforms are pushing iterative design cycles and rapid prototype testing, while established pharmaceutical firms are leveraging manufacturing scale, regulatory expertise, and global commercial networks to prepare for potential large-scale deployment. Strategic partnerships between smaller innovators and large manufacturers are common, combining nimble science with capacity for clinical-grade production and multi-market distribution.
Philanthropic funders, global health agencies, and consortia are playing a critical role in aligning incentives, supporting late-stage trials, and facilitating access-oriented clauses in licensing agreements. Contract development and manufacturing organizations have become essential ecosystem players by offering specialized fill-finish services and flexible capacity that can be repurposed across platforms. Research institutions and clinical consortia contribute essential translational science, enabling the identification of immune correlates and the design of rigorous endpoints for both preventive and therapeutic candidates. Observing these dynamics, organizations that maintain clear collaboration frameworks, prioritize scalable manufacturing partnerships, and invest in regulatory readiness are best positioned to navigate the pathway from candidate selection to real-world implementation.
Actionable recommendations for leaders to fortify R&D agility, scale manufacturing, secure diversified supply chains, and embed equitable access commitments
Industry leaders should adopt a dual-focus strategy that simultaneously accelerates scientific validation and strengthens operational resilience. Prioritize platform diversification to avoid single-point supply vulnerabilities and to enable adaptive prime-boost regimens that harness complementary immunogenic mechanisms. Invest in modular manufacturing architectures and technology transfer capabilities that facilitate rapid scaling and regional production, recognizing that supply chain localization reduces exposure to tariff and logistic disruptions. Establish robust regulatory engagement early in development, leveraging adaptive trial designs and pre-agreed immunological endpoints to shorten decision cycles while maintaining safety standards.
Forge multi-party collaborations that align incentives across biotechs, large manufacturers, funders, and local health systems, ensuring access commitments and capacity building are embedded in development agreements. Optimize distribution pathways by testing channel strategies-direct sales, online ordering for specific markets, and partnerships with retail pharmacies-tailored to regional procurement behaviors and cold-chain realities. Finally, integrate market intelligence and scenario planning into R&D prioritization so that investments in platform research, adjuvant technologies, and administration routes are informed by likely deployment constraints and end-user preferences, thereby increasing the probability of successful adoption when candidates meet clinical endpoints.
Rigorous mixed-methods research methodology combining expert interviews, supply chain mapping, and literature synthesis to support practical decision-making
This report synthesizes primary and secondary research using a mixed-methods approach to ensure analytical rigor and practical relevance. Primary inputs include expert interviews with industry leaders across biotechnology, pharmaceutical manufacturing, clinical research, and public health; structured dialogues with regulatory advisors; and consultations with procurement and supply chain specialists to capture operational realities. Secondary research encompassed peer-reviewed literature on immunology and vaccine platform advances, regulatory guidance documents, and published clinical trial protocols to ground analysis in contemporary scientific and policy frameworks.
Qualitative insights were triangulated with supply chain mapping exercises and technology readiness assessments to identify bottlenecks and opportunities for scale-up. Methodological safeguards included cross-validation of interview findings, a documented audit trail for data sources, and sensitivity checks around assumptions related to manufacturing lead times and distribution scenarios. The result is a synthesis that balances deep technical understanding with pragmatic operational guidance, designed to support decision-makers in R&D planning, partner selection, and commercialization strategy without relying on proprietary market estimates.
A concise synthesis of scientific progress, operational imperatives, and collaborative pathways that together define the current trajectory for HIV vaccines
The ongoing evolution of HIV vaccine development is defined by converging scientific breakthroughs, shifting operational imperatives, and an increasingly collaborative ecosystem. Platform innovations such as conventional and self-amplifying mRNA, refined viral vectors, and advanced protein-based candidates are expanding the toolkit available to researchers and developers, while regulatory and financing shifts are enabling more adaptive and inclusive clinical programs. At the same time, external forces including tariff adjustments and global supply chain realignments are reshaping manufacturing and distribution strategies, emphasizing the importance of supply chain diversification and regional capacity building.
For stakeholders across the spectrum-from early-stage innovators to large manufacturers and health system purchasers-the imperative is to align scientific ambition with operational feasibility. By integrating segmentation-focused strategy, regional contextualization, and pragmatic manufacturing planning, organizations can increase the likelihood that promising candidates will translate into accessible, effective interventions. The collective progress to date suggests that coordinated action across science, policy, and industry practice remains the most credible pathway to achieving meaningful public health impact.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
197 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Advancements in mRNA-based HIV vaccine candidates demonstrating broader immune responses and durable protection
- 5.2. Development of mosaic antigen formulations aiming to target multiple HIV strains with enhanced coverage
- 5.3. Integration of broadly neutralizing antibody inducement approaches into next generation HIV vaccine research pipelines
- 5.4. Adoption of nanoparticle delivery systems to improve antigen stability and targeted immune activation in HIV vaccines
- 5.5. Initiation of large scale clinical trials focusing on preventative HIV vaccines in high incidence regions of sub-Saharan Africa
- 5.6. Collaboration between biotechnology firms and academic institutions to accelerate HIV vaccine candidate development and testing
- 5.7. Emerging regulatory frameworks facilitating accelerated approval pathways for promising HIV vaccine candidates with strong safety profiles
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. HIV Vaccines Market, by Vaccine Type
- 8.1. Preventive
- 8.1.1. Peptide Vaccines
- 8.1.2. Live-attenuated Vaccines
- 8.1.3. DNA Vaccines
- 8.1.4. mRNA Vaccines
- 8.2. Therapeutic
- 9. HIV Vaccines Market, by Route Of Administration
- 9.1. Intramuscular
- 9.2. Intranasal
- 9.3. Subcutaneous
- 10. HIV Vaccines Market, by Target Antigen
- 10.1. Envelope Glycoproteins (Env)
- 10.2. Internal Gag Protein
- 10.3. Pol Proteins
- 11. HIV Vaccines Market, by End User
- 11.1. Clinics
- 11.2. Hospitals
- 11.3. Research Institutes
- 11.4. Public Health Agencies & Governments
- 12. HIV Vaccines Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. HIV Vaccines Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. HIV Vaccines Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Moderna, Inc.
- 15.3.2. Sanofi S.A.
- 15.3.3. Afrigen Biologics
- 15.3.4. AlphaVax, Inc.
- 15.3.5. Argos Therapeutics, Inc.
- 15.3.6. AstraZeneca PLC
- 15.3.7. Bavarian Nordic A/S
- 15.3.8. Immunor AS
- 15.3.9. BioNTech SE
- 15.3.10. Boehringer Ingelheim International GmbH
- 15.3.11. Celldex Therapeutics, Inc.
- 15.3.12. Cipla Limited
- 15.3.13. Excision BioTherapeutics, Inc.
- 15.3.14. F. Hoffmann-La Roche, Ltd
- 15.3.15. GeneCure Biotechnologies
- 15.3.16. Genetic Immunity, Inc.
- 15.3.17. GeoVax Labs, Inc.
- 15.3.18. Gilead Sciences, Inc.
- 15.3.19. GlaxoSmithKline PLC
- 15.3.20. ImmunityBio, Inc.
- 15.3.21. Immuno Cure BioTech Limited
- 15.3.22. Immunocore Holdings plc
- 15.3.23. Inovio Pharmaceuticals, Inc.
- 15.3.24. Johnson & Johnson Services, Inc.
- 15.3.25. Merck & Co., Inc.
- 15.3.26. Oncolys BioPharma Inc.
- 15.3.27. Pfizer Inc.
- 15.3.28. Sumagen Canada Inc
- 15.3.29. TVAX Biomedical, Inc.
- 15.3.30. ViiV Healthcare
- 15.3.31. Vir Biotechnology, Inc
- 15.3.32. Theravectys
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
